Nasal Polyps
FDA OKs fluticasone propionate nasal spray for chronic rhinosinusitis without nasal polyps
The FDA has approved fluticasone propionate nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients aged 18 years and older, according to an Optinose press release.
Most dupilumab use for asthma, CRSwNP categorized as persistent
Researchers characterized the use of dupilumab among a cohort of patients with asthma, chronic rhinosinusitis with nasal polyps or both as persistent in a study published in Annals of Allergy, Asthma & Immunology.
Top in allergy/asthma: Chronic rhinosinusitis with nasal polyps; food allergy testing
In patients with chronic rhinosinusitis with nasal polyps, treatment with Dupixent was associated with improvements in sleep quality and decreased insomnia, according to a recent study.
Dupilumab improves sleep among patients with chronic rhinosinusitis with nasal polyps
Sleep improved for patients with chronic rhinosinusitis with nasal polyps after a month of treatment with dupilumab, according to a study published in Annals of Allergy, Asthma & Immunology.
Symptom patterns emerge in NSAID-exacerbated respiratory disease development
Age, sex, ethnicity, BMI and environmental exposures were associated with different patterns in NSAID-exacerbated respiratory disease development, according to a study in The Journal of Allergy and Clinical Immunology: In Practice.
Parameters guide treatment for chronic rhinosinusitis with nasal polyps
The Allergy-Immunology Joint Task Force on Practice Parameters has issued guidelines for the medical management of chronic rhinosinusitis with nasal polyps, according to a review published in Annals of Allergy, Asthma & Immunology.
Dupilumab improves CRSwNP outcomes across type 2 inflammation profiles
Dupilumab improved outcomes among patients with severe chronic rhinosinusitis with nasal polyps across a range of type 2 inflammatory signatures, according to data presented at EAACI Hybrid Congress 2023 in Hamburg, Germany.
Dupilumab improves aspirin tolerance in NSAID-exacerbated respiratory disease
Following 6 months of dupilumab treatment, 57% of patients with NSAID-exacerbated respiratory disease had higher aspirin tolerance than before treatment, according to study results published in European Respiratory Journal.
Dupilumab shows long-term efficacy among asthma patients with, without CRSwNP
Long-term treatment with dupilumab appeared effective among patients with asthma with or without coexisting chronic rhinosinusitis with nasal polyps, according to a study published in Annals of Allergy, Asthma & Immunology.
Dupilumab improves CRSwNP outcomes despite severity of baseline loss of smell
LOUISVILLE, Ky. — Dupilumab improved symptoms among patients with chronic rhinosinusitis with nasal polyps regardless of baseline severity of smell loss, according to study results.